AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NKTX
  4. [Form 4] Nkarta, Inc. Insider Trading Activity

[Form 4] Nkarta, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Nkarta reported a significant insider transaction involving Chief Medical Officer and Head of R&D, Shawn Marshall Rose. On June 23, 2025, Rose was granted stock options to purchase 500,000 shares of common stock at an exercise price of $1.75 per share.

The stock options have a structured vesting schedule:

  • 25% of the options vest on July 23, 2026
  • Remaining 75% vest in 36 equal monthly installments following June 23, 2026
  • Options expire on June 22, 2035

This grant suggests a long-term retention strategy for a key executive, with the low exercise price potentially indicating recent stock price challenges or an incentive-focused compensation structure. The substantial size of the grant (500,000 shares) reflects the senior leadership position and importance of the R&D function to the company.

Nkarta ha comunicato una significativa operazione interna riguardante il Chief Medical Officer e Responsabile R&D, Shawn Marshall Rose. Il 23 giugno 2025, a Rose sono state assegnate opzioni su azioni per acquistare 500.000 azioni ordinarie a un prezzo di esercizio di 1,75 $ per azione.

Le opzioni azionarie prevedono un piano di maturazione strutturato:

  • 25% delle opzioni maturano il 23 luglio 2026
  • Il restante 75% matura in 36 rate mensili uguali a partire dal 23 giugno 2026
  • Le opzioni scadono il 22 giugno 2035

Questa assegnazione indica una strategia di retention a lungo termine per un dirigente chiave, con il prezzo di esercizio basso che potrebbe riflettere recenti difficolt脿 nel prezzo delle azioni o una struttura di compenso orientata agli incentivi. La consistente entit脿 dell鈥檃ssegnazione (500.000 azioni) sottolinea la posizione di vertice e l鈥檌mportanza della funzione R&D per l鈥檃zienda.

Nkarta inform贸 una transacci贸n interna significativa que involucra al Director M茅dico y Jefe de I+D, Shawn Marshall Rose. El 23 de junio de 2025, a Rose se le otorgaron opciones sobre acciones para comprar 500,000 acciones comunes a un precio de ejercicio de $1.75 por acci贸n.

Las opciones tienen un calendario de adquisici贸n estructurado:

  • 25% de las opciones se adquieren el 23 de julio de 2026
  • El 75% restante se adquiere en 36 cuotas mensuales iguales a partir del 23 de junio de 2026
  • Las opciones expiran el 22 de junio de 2035

Esta concesi贸n sugiere una estrategia de retenci贸n a largo plazo para un ejecutivo clave, con el bajo precio de ejercicio que podr铆a indicar recientes desaf铆os en el precio de las acciones o una estructura de compensaci贸n basada en incentivos. El tama帽o considerable de la concesi贸n (500,000 acciones) refleja la posici贸n de liderazgo senior y la importancia de la funci贸n de I+D para la compa帽铆a.

Nkarta電� 斓滉碃 鞚橂 毂呾瀯鞛愳澊鞛� 鞐瓣惮臧滊皽 毂呾瀯鞛愳澑 Shawn Marshall Rose鞕� 甏�霠悳 欷戩殧頃� 雮措秬 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 23鞚�, Rose鞐愱矊 氤错喌欤� 500,000欤�毳� 欤茧嫻 $1.75鞚� 頄夓偓臧�瓴╈溂搿� 甑Г頃� 靾� 鞛堧姅 鞀ろ啞鞓奠厴鞚� 攵�鞐悩鞐堨姷雼堧嫟.

鞀ろ啞鞓奠厴鞚� 雼れ潓瓿� 臧欖潃 甓岆Μ 旆摑 鞚检爼鞚� 鞛堨姷雼堧嫟:

  • 25%電� 2026雲� 7鞗� 23鞚检棎 甓岆Μ 旆摑
  • 雮橂ǜ歆赌 75%電� 2026雲� 6鞗� 23鞚� 鞚错泟 36臧滌洈鞐� 瓯胳硱 毵れ洈 攴犽摫頃橁矊 甓岆Μ 旆摑
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 22鞚�

鞚措矆 攵�鞐姅 頃奠嫭 鞛勳洂鞚� 鞛リ赴 鞙犾 鞝勲灥鞚� 鞚橂頃橂┌, 雮潃 頄夓偓臧�瓴╈潃 斓滉芳 欤缄皜 頃橂澖鞚措倶 鞚胳劶韹半笇 欷戩嫭 氤挫儊 甑“毳� 氚橃榿頃� 靾� 鞛堨姷雼堧嫟. 500,000欤茧澕電� 韥� 攴滊電� 瓿犾渼 毽崝鞁� 鞙勳箻鞕� 須岇偓 雮� 鞐瓣惮臧滊皽 旮半姤鞚� 欷戩殧靹膘潉 雮橅儉雰呺媹雼�.

Nkarta a annonc茅 une transaction importante en interne impliquant le Directeur M茅dical et Responsable R&D, Shawn Marshall Rose. Le 23 juin 2025, Rose s鈥檈st vu attribuer des options d鈥檃chat portant sur 500 000 actions ordinaires 脿 un prix d鈥檈xercice de 1,75 $ par action.

Les options d鈥檃chat suivent un calendrier d鈥檃cquisition structur茅 :

  • 25% des options seront acquises le 23 juillet 2026
  • Les 75% restants seront acquis en 36 versements mensuels 茅gaux 脿 partir du 23 juin 2026
  • Les options expirent le 22 juin 2035

Cette attribution sugg猫re une strat茅gie de r茅tention 脿 long terme pour un cadre cl茅, le faible prix d鈥檈xercice pouvant indiquer des difficult茅s r茅centes du cours de l鈥檃ction ou une structure de r茅mun茅ration ax茅e sur les incitations. L鈥檌mportance notable de cette attribution (500 000 actions) refl猫te la position de direction senior et l鈥檌mportance de la fonction R&D pour l鈥檈ntreprise.

Nkarta meldete eine bedeutende Insider-Transaktion mit dem Chief Medical Officer und Leiter der F&E, Shawn Marshall Rose. Am 23. Juni 2025 erhielt Rose Aktienoptionen zum Kauf von 500.000 Stammaktien zu einem Aus眉bungspreis von 1,75 $ pro Aktie.

Die Aktienoptionen unterliegen einem gestaffelten Vesting-Plan:

  • 25% der Optionen werden am 23. Juli 2026 f盲llig
  • Die restlichen 75% werden in 36 gleichen monatlichen Raten ab dem 23. Juni 2026 眉bertragen
  • Die Optionen verfallen am 22. Juni 2035

Diese Zuteilung deutet auf eine langfristige Bindungsstrategie f眉r einen wichtigen F眉hrungskraft hin, wobei der niedrige Aus眉bungspreis m枚glicherweise auf j眉ngste Kursprobleme oder eine anreizorientierte Verg眉tungsstruktur hindeutet. Die betr盲chtliche Gr枚脽e der Zuteilung (500.000 Aktien) spiegelt die leitende F眉hrungsposition und die Bedeutung der F&E-Funktion f眉r das Unternehmen wider.

Positive
  • Chief Medical Officer received a significant stock option grant of 500,000 shares at $1.75 exercise price, representing strong long-term alignment with shareholders
Negative
  • None.

Nkarta ha comunicato una significativa operazione interna riguardante il Chief Medical Officer e Responsabile R&D, Shawn Marshall Rose. Il 23 giugno 2025, a Rose sono state assegnate opzioni su azioni per acquistare 500.000 azioni ordinarie a un prezzo di esercizio di 1,75 $ per azione.

Le opzioni azionarie prevedono un piano di maturazione strutturato:

  • 25% delle opzioni maturano il 23 luglio 2026
  • Il restante 75% matura in 36 rate mensili uguali a partire dal 23 giugno 2026
  • Le opzioni scadono il 22 giugno 2035

Questa assegnazione indica una strategia di retention a lungo termine per un dirigente chiave, con il prezzo di esercizio basso che potrebbe riflettere recenti difficolt脿 nel prezzo delle azioni o una struttura di compenso orientata agli incentivi. La consistente entit脿 dell鈥檃ssegnazione (500.000 azioni) sottolinea la posizione di vertice e l鈥檌mportanza della funzione R&D per l鈥檃zienda.

Nkarta inform贸 una transacci贸n interna significativa que involucra al Director M茅dico y Jefe de I+D, Shawn Marshall Rose. El 23 de junio de 2025, a Rose se le otorgaron opciones sobre acciones para comprar 500,000 acciones comunes a un precio de ejercicio de $1.75 por acci贸n.

Las opciones tienen un calendario de adquisici贸n estructurado:

  • 25% de las opciones se adquieren el 23 de julio de 2026
  • El 75% restante se adquiere en 36 cuotas mensuales iguales a partir del 23 de junio de 2026
  • Las opciones expiran el 22 de junio de 2035

Esta concesi贸n sugiere una estrategia de retenci贸n a largo plazo para un ejecutivo clave, con el bajo precio de ejercicio que podr铆a indicar recientes desaf铆os en el precio de las acciones o una estructura de compensaci贸n basada en incentivos. El tama帽o considerable de la concesi贸n (500,000 acciones) refleja la posici贸n de liderazgo senior y la importancia de la funci贸n de I+D para la compa帽铆a.

Nkarta電� 斓滉碃 鞚橂 毂呾瀯鞛愳澊鞛� 鞐瓣惮臧滊皽 毂呾瀯鞛愳澑 Shawn Marshall Rose鞕� 甏�霠悳 欷戩殧頃� 雮措秬 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 23鞚�, Rose鞐愱矊 氤错喌欤� 500,000欤�毳� 欤茧嫻 $1.75鞚� 頄夓偓臧�瓴╈溂搿� 甑Г頃� 靾� 鞛堧姅 鞀ろ啞鞓奠厴鞚� 攵�鞐悩鞐堨姷雼堧嫟.

鞀ろ啞鞓奠厴鞚� 雼れ潓瓿� 臧欖潃 甓岆Μ 旆摑 鞚检爼鞚� 鞛堨姷雼堧嫟:

  • 25%電� 2026雲� 7鞗� 23鞚检棎 甓岆Μ 旆摑
  • 雮橂ǜ歆赌 75%電� 2026雲� 6鞗� 23鞚� 鞚错泟 36臧滌洈鞐� 瓯胳硱 毵れ洈 攴犽摫頃橁矊 甓岆Μ 旆摑
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 22鞚�

鞚措矆 攵�鞐姅 頃奠嫭 鞛勳洂鞚� 鞛リ赴 鞙犾 鞝勲灥鞚� 鞚橂頃橂┌, 雮潃 頄夓偓臧�瓴╈潃 斓滉芳 欤缄皜 頃橂澖鞚措倶 鞚胳劶韹半笇 欷戩嫭 氤挫儊 甑“毳� 氚橃榿頃� 靾� 鞛堨姷雼堧嫟. 500,000欤茧澕電� 韥� 攴滊電� 瓿犾渼 毽崝鞁� 鞙勳箻鞕� 須岇偓 雮� 鞐瓣惮臧滊皽 旮半姤鞚� 欷戩殧靹膘潉 雮橅儉雰呺媹雼�.

Nkarta a annonc茅 une transaction importante en interne impliquant le Directeur M茅dical et Responsable R&D, Shawn Marshall Rose. Le 23 juin 2025, Rose s鈥檈st vu attribuer des options d鈥檃chat portant sur 500 000 actions ordinaires 脿 un prix d鈥檈xercice de 1,75 $ par action.

Les options d鈥檃chat suivent un calendrier d鈥檃cquisition structur茅 :

  • 25% des options seront acquises le 23 juillet 2026
  • Les 75% restants seront acquis en 36 versements mensuels 茅gaux 脿 partir du 23 juin 2026
  • Les options expirent le 22 juin 2035

Cette attribution sugg猫re une strat茅gie de r茅tention 脿 long terme pour un cadre cl茅, le faible prix d鈥檈xercice pouvant indiquer des difficult茅s r茅centes du cours de l鈥檃ction ou une structure de r茅mun茅ration ax茅e sur les incitations. L鈥檌mportance notable de cette attribution (500 000 actions) refl猫te la position de direction senior et l鈥檌mportance de la fonction R&D pour l鈥檈ntreprise.

Nkarta meldete eine bedeutende Insider-Transaktion mit dem Chief Medical Officer und Leiter der F&E, Shawn Marshall Rose. Am 23. Juni 2025 erhielt Rose Aktienoptionen zum Kauf von 500.000 Stammaktien zu einem Aus眉bungspreis von 1,75 $ pro Aktie.

Die Aktienoptionen unterliegen einem gestaffelten Vesting-Plan:

  • 25% der Optionen werden am 23. Juli 2026 f盲llig
  • Die restlichen 75% werden in 36 gleichen monatlichen Raten ab dem 23. Juni 2026 眉bertragen
  • Die Optionen verfallen am 22. Juni 2035

Diese Zuteilung deutet auf eine langfristige Bindungsstrategie f眉r einen wichtigen F眉hrungskraft hin, wobei der niedrige Aus眉bungspreis m枚glicherweise auf j眉ngste Kursprobleme oder eine anreizorientierte Verg眉tungsstruktur hindeutet. Die betr盲chtliche Gr枚脽e der Zuteilung (500.000 Aktien) spiegelt die leitende F眉hrungsposition und die Bedeutung der F&E-Funktion f眉r das Unternehmen wider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rose Shawn Marshall
(Last) (First) (Middle)
1150 VETERANS BLVD
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Nkarta, Inc. [ NKTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $1.75 06/23/2025 A 500,000 (1) 06/22/2035 Common Stock 500,000 $0 500,000 D
Explanation of Responses:
1. The option is scheduled to vest and become exercisable as to 25% of the shares subject to the grant on July 23, 2026. The remaining portion of the option is scheduled to vest and become exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 23, 2026.
Remarks:
Chief Medical Officer, Head of Research & Development
/s/ Bridgette Housley, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many stock options did NKTX's Chief Medical Officer receive on June 23, 2025?

NKTX's Chief Medical Officer, Shawn Marshall Rose, received 500,000 stock options with an exercise price of $1.75 per share on June 23, 2025.

What is the vesting schedule for NKTX CMO's stock options granted in June 2025?

The stock options vest over 4 years, with 25% vesting on July 23, 2026, and the remaining 75% vesting in 36 equal monthly installments following June 23, 2026.

What is the expiration date for NKTX CMO's stock options granted in June 2025?

The stock options granted to NKTX's Chief Medical Officer expire on June 22, 2035, ten years after the grant date.

What is the exercise price of the stock options granted to NKTX's CMO in June 2025?

The exercise price of the stock options granted to NKTX's Chief Medical Officer is $1.75 per share.

Who is NKTX's Chief Medical Officer and Head of Research & Development as of June 2025?

Shawn Marshall Rose serves as NKTX's Chief Medical Officer and Head of Research & Development, based at 1150 Veterans Blvd, South San Francisco, CA.
Stock NKTX logo
Nkarta, Inc.

NASDAQ:NKTX

NKTX Rankings

#4390 Ranked by Market Cap
N/A Ranked by Dividends

NKTX Latest News

Aug 12, 2025
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
Jul 23, 2025
Nkarta to Participate in the H.C. Wainwright 鈥淗CW@Home鈥� Series
Jun 6, 2025
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
May 14, 2025
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Apr 1, 2025
Nkarta to Participate in an April Investor Conference

NKTX Latest SEC Filings

Aug 12, 2025
[10-Q] Nkarta, Inc. Quarterly Earnings Report
Aug 12, 2025
[8-K] Nkarta, Inc. Reports Material Event
Jun 25, 2025
[Form 3] Nkarta, Inc. Initial Statement of Beneficial Ownership
Jun 20, 2025
[Form 4] Nkarta, Inc. Insider Trading Activity

NKTX Stock Data

142.62M
66.31M
5.02%
91.59%
10.71%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO